Human Epidermal Growth Factor 2 Negative Carcinoma Of Breast — Patent Landscape

Aggregated US Orange Book patent estate across every approved drug for human epidermal growth factor 2 negative carcinoma of breast. 29 active patents protecting 2 drugs from 2+ originators. First major cliff: 2031. Daily refresh.

2
Approved drugs
29
Active US patents
64/100
Avg vulnerability
$6.3B
Annual revenue covered

Originators in Human Epidermal Growth Factor 2 Negative Carcinoma Of Breast

Companies holding active patents on drugs approved for this indication. Click through to each company's full patent dashboard.

AstraZeneca 25 patents Eli Lilly 4 patents

Cliff calendar — next 15 years

Patent expiries per year across all drugs treating human epidermal growth factor 2 negative carcinoma of breast. Each bar = one year. Y-axis scaled to peak year (12 patents).

7
27
1
28
12
29
7
31

Approved drugs ranked by patent estate

Drug Originator Active patents Avg vuln Revenue First cliff
Lynparza
olaparib
 AstraZeneca 25 59 $2.6B 2027-08-12
Verzenio
abemaciclib
 Eli Lilly 4 68 $3.7B 2031-09-28

Most attackable patents

Highest vulnerability scores in the indication — paragraph IV / IPR / design-around candidates.

Patent Drug Type Vuln Expiry
8143241 Lynparza method of use 75 2027-08-12
8071579 Lynparza method of use 75 2027-08-12
8143241 Lynparza method of use 75 2027-08-12
8143241 Lynparza method of use 75 2027-08-12
8071579 Lynparza method of use 75 2027-08-12
11970530 Lynparza method of use 75 2041-10-25
11970530 Lynparza method of use 75 2041-10-25
8859562 Lynparza method of use 68 2031-08-04
8859562 Lynparza method of use 68 2031-08-04
8859562 Lynparza method of use 68 2031-08-04

Strongest defences

Lowest vulnerability scores — pillars of the indication's IP fortress.

Patent Drug Type Vuln Expiry
8247416 Lynparza composition of matter 17 2028-09-24
7449464 Lynparza composition of matter 17 2027-09-08
7449464 Lynparza composition of matter 17 2027-09-08
8475842 Lynparza formulation 48 2029-12-31
8475842 Lynparza formulation 48 2029-12-31
11633396 Lynparza formulation 56 2029-10-07
11633396 Lynparza formulation 56 2029-10-07
12178816 Lynparza formulation 61 2029-10-07
12144810 Lynparza formulation 61 2029-10-07
12048695 Lynparza formulation 61 2029-10-07

Related